Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test
Submission includes a concurrent CLIA Waiver by Application for use of the test on the Co-Dx PCR Pro® instrument in decentralized point-of-care settings.
Co-Diagnostics Raises Capital Through Warrant Inducement Ahead of FDA Review
A company still awaiting its first FDA clearance just structured a capital raise around the urgency of that wait. On July 30, 2026, Co-Diagnostics, Inc. entered into a warrant inducement agreement with existing warrant holders, convincing them to exercise warrants early in exchange for new warrants at revised terms. The transaction is straightforward on its […]
Co-Diagnostics Hosts Kingdom of Saudi Arabia Joint Venture CoMira for Unveiling of Future Automated Manufacturing Line
Visit has included tour of Utah headquarters and automated manufacturing facilities ahead of planned technology transfer.
Co-Diagnostics Advances Ebola PCR Assay Development Strategy with Joint Venture CoSara
Joint development strategy has been developed to address international deployment requirements if current outbreak continues or expands globally
Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
Recent pathogens illustrate need for improved situational awareness capabilities, such as those provided by the Co-Dx PCR point-of-care platform
Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies
The Australian patent represents the first patent granted for the Company’s new point-of-care testing platform.
Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India
Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India
Co-Diagnostics to Integrate and Implement Proprietary Artificial Intelligence Technology into Co-Dx™ Primer Ai™ Platform
Company forms new AI business unit, led by Chief Technology & AI Officer Christopher Thurston, to unify and advance Co-Dx’s existing and future AI initiatives
Co-Diagnostics, Inc. Signs Strategic MOU with Partner in Kingdom of Saudi Arabia to Introduce Co-Dx™ PCR Platform to Middle East
The Memorandum of Understanding includes the formation of a Joint Venture in the Kingdom of Saudi Arabia for manufacturing and distribution of the Company’s upcoming Co-Dx™ PCR platform and other Co-Dx IP
Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Influenza Multiplex PCR Test
The clinical laboratory real-time PCR multiplex test was designed using Co-Dx Co-Primers™ and licensed by the CDSCO for use in diagnostic procedures
Co-Diagnostics, Inc. Reports Second Quarter 2022 Financial Results
Second quarter results impacted by volume declines; Further progress on the development of the Co-Dx PCR Home platform
Co-Diagnostics, Inc. to Announce Expansion of OEM Agreement with Bio Molecular Systems at AACC
Co-Diagnostics announced that it will be disclosing the global expansion of its OEM agreement with Bio Molecular Systems (BMS) at the Company’s customer and distributor update today at AACC.
